张轲课题组 
Neurological Disease Laboratory at SZBL

​刘萌/Meng Liu

2025 广东药科大学,基础医学,医学硕士

2022 山西医科大学,医学检验技术,理学学士


2025 M.M. Guangdong Pharmaceutical University

2022 B.S. Shanxi Medical University





发表文章/Publications:

1.Liu M, Xuan A, Zheng L, et al. (2025)Novel coumarin derivative SZC-6 as an allosteric activator of SIRT3 alleviates diabetic kidney disease via the SIRT3-Foxo3a signaling axis. Free Radic Biol Med.240:29-45. 

2.Xuan A, Liu M, Zhang L, et al. (2025)SZC-6 Promotes Diabetic Wound Healing in Mice by Modulating the M1/M2 Macrophage Ratio and Inhibiting the MyD88/NF-χB Pathway. Pharmaceuticals (Basel).18(8):1143. 

3.Liu H, Chen Z, Liu M, Li E, Shen J, Wang J, Liu W, Jin X. (2024) The Terminalia chebula Retz extract treats hyperuricemic nephropathy by inhibiting TLR4/MyD88/NF-κB axis. J Ethnopharmacol. 322:117678.